Heart Test Laboratories Inc. Common Stock
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting… Read more
Heart Test Laboratories Inc. Common Stock (HSCS) - Total Liabilities
Latest total liabilities as of October 2025: $1.81 Million USD
Based on the latest financial reports, Heart Test Laboratories Inc. Common Stock (HSCS) has total liabilities worth $1.81 Million USD as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Heart Test Laboratories Inc. Common Stock - Total Liabilities Trend (2020–2025)
This chart illustrates how Heart Test Laboratories Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Heart Test Laboratories Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Heart Test Laboratories Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mooncor Oil & Gas Corp
V:MOO
|
Canada | CA$38.27 Million |
|
Cara Therapeutic
NASDAQ:CARA
|
USA | $48.42 Million |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
Indonesia | Rp2.31 Trillion |
|
Jufan Industrial Co., Ltd.
TWO:4584
|
Taiwan | NT$921.89 Million |
|
Cambium Bio Ltd
AU:CMB
|
Australia | AU$1.46 Million |
|
Gihon Telekomunikasi Indonesia Tbk PT
JK:GHON
|
Indonesia | Rp586.75 Billion |
|
Komputronik S.A.
WAR:KOM
|
Poland | zł251.25 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Heart Test Laboratories Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heart Test Laboratories Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heart Test Laboratories Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Heart Test Laboratories Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $4.02 Million | +83.81% |
| 2024-04-30 | $2.19 Million | -28.49% |
| 2023-04-30 | $3.06 Million | -62.47% |
| 2022-04-30 | $8.15 Million | +112.28% |
| 2021-04-30 | $3.84 Million | +133.92% |
| 2020-04-30 | $1.64 Million | -- |